环孢素A逆转了一名继发于胸腺瘤的纯红细胞再生障碍性贫血患者的化疗耐药性。

Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma.

作者信息

Li Peng, Du Fengcai, Gong Zhaohua, Hu Baohong, Chi Cheng, Chu Hongjin, Chen Jian

机构信息

Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China.

The First Clinical College of DaLian Medical University, DaLian, P.R. China.

出版信息

Anticancer Res. 2017 Aug;37(8):4611-4614. doi: 10.21873/anticanres.11861.

DOI:10.21873/anticanres.11861

PMID:28739760

Abstract

This case study reports on a patient who relapsed with thymoma (mixed type) nine years after tumor resection. After four courses of rescue chemotherapy (docetaxel and cisplatinum), the patient was further diagnosed with pure red cell aplasia. It was noticed that cyclosporin A (CsA), which was administered to treat aplasia, could reverse chemoresistance. Its mechanism is not completely clear, but the hypothesis of CsA inhibiting P-glycoprotein mediated drug efflux is the most acceptable.

摘要

本病例报告了一名患者，其在肿瘤切除九年后复发胸腺瘤（混合型）。经过四个疗程的挽救性化疗（多西他赛和顺铂）后，该患者被进一步诊断为纯红细胞再生障碍性贫血。注意到用于治疗再生障碍性贫血的环孢素A（CsA）可逆转化疗耐药性。其机制尚不完全清楚，但CsA抑制P-糖蛋白介导的药物外排这一假说最为可信。